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doi:10.1Objective: Effectiveness of preoperative and postoperative extracorporeal membrane oxygenation support in pe-
diatric lung transplantation was studied.
Methods: Institutional database of pediatric lung transplants from 1990 to 2008 was reviewed.
Results: Three hundred forty-four patients underwent lung transplants in the study period. Thirty-three of 344
patients (9.6%) required perioperative extracorporeal membrane oxygenation support. Fifteen patients (median,
age 1.3 years; range, 0.2–18 years) required 16 pretransplant extracorporeal membrane oxygenation runs. Indi-
cations were respiratory failure (8/16, 50%), severe pulmonary hypertension (5/16, 31%), and cardiopulmonary
collapse (3/16, 19%). Four of these patients (27%) also required postoperative support. Six (40%) were weaned
before lung transplant. Six (40%) survived to hospital discharge. Survival to discharge was higher among patients
weaned before lung transplant (4/6, 66% vs 2/9, 22%). Twenty-two patients (median age, 9.4 years; range, 0.2–
21 years) underwent 24 extracorporeal membrane oxygenation runs after lung transplant. Indications for postop-
erative support were primary graft dysfunction (18/24, 75%), pneumonia (4/24, 16%), and others (2/24, 9%).
Median time between lung transplant and institution of extracorporeal membrane oxygenation was 32 hours
(range, 0–1084 hours); median duration of support was 141 hours (range, 48–505 hours). Five of these patients
(23%) survived to hospital discharge. Among nonsurvivors, causes of death were intractable respiratory failure
(12/17, 70%) and infectious complications (4/17, 24%).
Conclusions:Need for perioperative extracorporeal membrane oxygenation support is associated with significant
morbidity and mortality among pediatric patients receiving lung transplants. A subset of patients who can
be weaned from support preoperatively have greater likelihood of survival. (J Thorac Cardiovasc Surg
2010;140:427-32)T
XLung transplants now provide well-accepted therapy for
end-stage lung disease in both children and adults. Primary
graft dysfunction (PGD) is the leading cause of early mortal-
ity after lung transplant.1 Despite improvements in surgical
and preservation techniques, PGD is common after lung
transplants, and severe PGD occurs in 13% to 35% of
patients.2
The severity of PGD and its attendant effects on other or-
gan systems dictate therapy. Treatment may range from ob-
servation alone to extracorporeal membrane oxygenation
(ECMO) support. Several series from leading transplant cen-
ters have described their experience with extracorporeal sup-
port in the postoperative period for adult patients and have
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The Journal of Thoracic and CaExtracorporeal Life Support Organization registry showed
151 cases, with a 42% rate of survival to hospital
discharge.9 There is, however, only a small body of evidence
regarding the use of ECMO in pediatric patients in the post-
transplant setting.10
Patients awaiting a lung transplant may require respira-
tory support, which may range from mechanical ventilation
to ECMO support. Reports on the use of ECMO as a bridge
to lung transplant are isolated,11,12 and the outcomes remain
mixed.10-12 Many centers have considered ECMO to be
a contraindication to lung transplant. Again, there are few
data on outcomes among pediatric patients who require
extracorporeal support while awaiting a lung transplant.10
We initiated a pediatric lung transplant program at our
center in 1990. We describe here our experience with the
use of preoperative and postoperative ECMO support for
patients receiving lung transplants.MATERIALS AND METHODS
Operative Management
In general, the transplant techniques have been consistent through time
and operations were performed as previously described.13,14 Virtually all
the operations were performed with cardiopulmonary bypass because of
the difficulties of double-lumen endotracheal tube use in children and the
prevalence of pulmonary hypertension in the pediatric cohort.rdiovascular Surgery c Volume 140, Number 2 427
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
PGD ¼ primary graft dysfunction
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A standardized ECMO perfusion circuit was used, with appropriately
sized cannulas for patient size. The venoarterial configuration was used
for all but 1 patient, who was placed on venovenous ECMO support. Trans-
cervical cannulation was used for most patients who required ECMO before
lung transplant. Typically, the right carotid artery and internal jugular veins
were used. If transthoracic cannulation was used, the aorta and right atrium
were cannulated. Among patients who required ECMO support after lung
transplantation, transthoracic cannulation was used for patients who re-
quired support during the immediate postoperative period, whereas trans-
cervical cannulation was preferred for patients with delayed presentation.
Pump flows were regulated on the basis of systemic perfusion, oxygen-
ation, and mixed venous oxygenation. Pharmacologic support was weaned
as tolerated, and patients were maintained with prophylactic antibiotics to
cover gram-positive organisms unless culture-directed antibiotic coverage
was indicated.
ECMO support was continued until one of the following end points was
achieved: recovery of function sufficient to support stable oxygenation, gas
exchange, and hemodynamics; availability of a transplant organ; or devel-
opment of complications rendering the patient a noncandidate for transplant
or recovery. There was no preset time limit for ECMO support.
Postoperative Management
In general, routine postoperative management was consistent during the
period analyzed and has been described elsewhere.15
Patients
This single-center retrospective study examined outcomes of lung trans-
plants among children who required ECMO support in the preoperative or
postoperative period. An electronic database was queried to obtain data re-
garding the indications for and outcomes of all lung transplants performed
between 1990 and 2008 at St Louis Children’s Hospital at Washington Uni-
versity. Individual patient records were consulted to verify missing, incom-
plete or suspect data. The patients in this report include all patients that
underwent deceased donor or living donor lung transplantation at Children’s
Hospital from 1990 through 2008. Institutional review board approval was
obtained for the study, and need for individual patient consent was waived
because of the minimal risk posed by the retrospective nature of the study.
Statistics
For this retrospective review, data are expressed as means unless other-
wise stated. Descriptive statistics are presented, because the small numbers
in the ECMO group preclude meaningful statistical comparisons between
the groups.RESULTS
Three hundred forty-four patients received lung trans-
plants during the study period. Thirty-three of these 344 pa-
tients (9.6%) required ECMO support in the perioperative
period.
Fifteen patients (median age, 1.3 years; range, 0.2–18
years) required 16 ECMO runs in the pretransplant period.
Their diagnoses were as follows: pulmonary hypertension428 The Journal of Thoracic and Cardiovascular Surg(n ¼ 4), surfactant deficiency (n ¼ 3), graft failure
(n¼ 3), congenital diaphragmatic hernia (n¼ 2), pulmonary
vein obstruction (n ¼ 2), and cystic fibrosis (n ¼ 1). The in-
dications for ECMO were respiratory failure in 8 of 16 cases
(50%), severe pulmonary hypertension in 5 of 16 (31%),
and cardiopulmonary collapse in 3 of 16 (19%). Vascular
access was venoarterial (16/16, 100%), with neck vessels
the preferred cannulation site (14/16, 87%).
Median duration of ECMO support was 234 hours (range,
8–576 hours). All patients survived through lung transplant,
and 4 of 15 (27%) required postoperative ECMO support as
well. Six of 15 patients (40%) were weaned from ECMO be-
fore lung transplant. Complications (sepsis, reexploration,
and massive bleeding) were seen in 10 of 16 ECMO runs
(63%).
Six of 15 patients with preoperative ECMO support
(40%) survived to hospital discharge. Survival to discharge
was higher among patients weaned from ECMO before lung
transplant (4/6, 66%) than among patients still receiving
ECMO support at lung transplant (2/9, 22%). None of the
patients who required both preoperative and postoperative
ECMO support (n¼ 4) survived to hospital discharge. In ad-
dition, none of the 3 patients receiving reoperative lung
transplants survived to hospital discharge.
Of the 6 patients in the preoperative ECMO group who
were discharged from the hospital, 5 survived to 1 year
and the other died of infectious complications at 261 days.
Table 1 shows the characteristics of the patients with preop-
erative ECMO support versus the general transplant popula-
tion without preoperative ECMO support. Table 2 compares
the survivors and nonsurvivors in the preoperative ECMO
support group. The number of patients is too small for mean-
ingful statistical comparisons. The nonsurvivors in the pre-
operative ECMO group were older than the survivors
because of inclusion of a patient with cystic fibrosis and 3
patients receiving reoperative lung transplants among the
nonsurvivors.
Twenty-two patients (median age, 9.4 years; range, 0.2–
18 years) underwent 24 ECMO runs after lung transplant
(Table 3). Their diagnoses were as follows: cystic fibrosis
(n ¼ 6), pulmonary hypertension (n ¼ 5), bronchiolitis ob-
literans (n ¼ 4), and others (n ¼ 7). The indications for
ECMO support were primary graft dysfunction in 18 of 24
cases (75%), pneumonia in 4 of 24 (16%), and others in 2
of 24 (9%). The median time between lung transplant and
institution of ECMO was 141 hours (range, 48–505 hours).
The median time was 660 hours for patients who required
ECMO for pneumonia.
Access was predominantly venoarterial (23/24, 96%), and
mean duration of ECMO support was 158 125 hours. Cen-
tral cannulation in the chest was used in 15 of 24 ECMO runs
(62.5%). Major complications were seen in 82% of patients.
Five of 22 patients (23%) survived to hospital discharge
(median survival, 5.8 years). Among the nonsurvivors, theery c August 2010
TABLE 2. Comparison of survivors and nonsurvivors among patients
who required extracorporeal membrane oxygenation before lung
transplant
Survivors Nonsurvivors
No. of transplants 6 9
Age (y, median and range) 0.73 (0.2–1.8) 1.1 (0.1–10.2)
Sex (female/male) 4:2 6:3
Diagnoses (no.)
Pulmonary hypertension (n ¼ 4) 2 (33%) 2 (18%)
Surfactant deficiency (n ¼ 3) 2 (33%) 1 (11%)
Graft failure (n ¼ 3) 0 3 (33%)
Congenital diaphragmatic
hernia (n ¼ 2)
1 (17%) 1 (11%)
Pulmonary vein obstruction (n ¼ 2) 1 (17%) 1 (11%)
Cystic fibrosis (n ¼ 1) 0 1 (11%)
Weaning from ECMO before
transplant (no.)
4 (66%) 2 (18%)
Duration of ECMO (h, median
and range)
281 (8–576) 227 (24–405)
ICU stay (d, median and range) 43 (11–90) 26.5 (7–110)
Hospital stay (d, median and range) 46 (21–118) 39 (7–118)
Ischemic time (min, median and range)
Left 272 290
Right 328 285
Posttransplant ECMO 0 (0%) 4 (44%)
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit.
TABLE 1. Comparison of patients who needed extracorporeal
membrane oxygenation before lung transplant with those who did not
Pretransplant ECMO
Yes No
No. of transplants 15 329
No. of preoperative ECMO runs 16 0
Age (y, median and range) 1.3 (0.2–18) 11 (0.2–18)
Sex (female/male) 10:5 180:149
Diagnoses (no.)
Pulmonary hypertension 4 (27%) 54 (16%)
Surfactant deficiency 3 (20%) 0
Graft failure 3 (20%) 41 (12%)
Congenital diaphragmatic hernia 2 (13%) 0
Pulmonary vein obstruction 2 (13%) 13 (4%)
Cystic fibrosis 1 (7%) 166 (51%)
Interstitial pneumonia or fibrosis 0 34 (10%)
Other 0 21 (7%)
Single/double transplant ratio 2:13 7:322
ICU stay (d, median and range) 46 (0–88) 7 (0–164)
Hospital stay (d, median and range) 46 (8–96) 19 (1–261)
Ischemic time (min, median and range)
Left 290 254
Right 315 305
Postoperative ECMO (no.) 4/15 (27%) 18/329 (5.5%)
Major complications* (no.) 10/16 (63%) 91/329 (27.6%)
Survival to discharge (no.) 6/15 (40%) 295/329 (89.7%)
Survival at 1 y (no.) 5/15 (33%) 264/329 (80.2%)
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit. *Major
complications were bleeding, stroke, reexploration, and infection.
Puri et al Cardiothoracic Transplantationcauses of death were intractable respiratory failure (12/17,
70%) and infectious complications (4/17, 24%; Table 4).
There were 18 patients who required ECMO support for
PGD. In this group, the median time between lung transplant
and institution of ECMO for PGD was 5 hours (range, 0–24
hours) for the 4 survivors and 40 hours (range, 0–408 h) for
the 14 non-survivors.T
XDISCUSSION
Main findings of our retrospective review are that children
who require ECMO support before or after lung transplanta-
tion have both high incidence of major morbidity and high
mortality. Kirshbom and colleagues10 reviewed their use
of ECMO in the perioperative setting in pediatric thoracic
organ transplantation and described major complication
rates of 60% and 55% in their pretransplant and posttrans-
plant ECMO groups, respectively. Our incidences of major
complications (bleeding, reexploration, major infection,
and stroke) in the preoperative and postoperative setting
were 63% and 82%, respectively.
There have been sporadic reports about use of ECMO as
a bridge to lung transplant.11,12 Jackson and coworkers11 re-
ported 3 of their own cases, all with successful bridging to
lung transplant, and summarized previous reports to showThe Journal of Thoracic and Caa 1-year survival of about 40% for ECMO as a bridge to
lung transplant in the adult population. Our 1-year survival
in a similar setting with use of preoperative ECMO in a pedi-
atric population was 33%. These numbers are significantly
lower than our 1-year survival of 80% in the general pediat-
ric lung transplant population without preoperative ECMO.
We were able to wean 6 of 15 patients (40%) from ECMO
in the preoperative setting, so technically these patients were
not bridged to lung transplant. It is in this population that we
saw our best outcomes, however, with 4 of these 6 patients
surviving to 1 year. Of the 9 patients still supported by
ECMO at the time of lung transplant, only 2 (18%) survived
to 1 year. Of the 2 survivors, 1 was given ECMO support for
only 8 hours, and lungs were already available at the time,
whereas the other survivor received ECMO for 24 days be-
fore lung transplant. On the basis of our suboptimal out-
comes for patients supported by ECMO while awaiting
a lung transplant, our current practice is to delist patients
with respiratory failure when ECMO is instituted.
It may appear from our report that all our patients listed for
lung transplant who needed preoperative ECMO support
received lung transplants. This is not the case, however, be-
cause this study selectively examined patients who received
lung transplants at our center, and the true denominator
would be the total number of patients with intractable respi-
ratory failure who received ECMO support. During the
study period, 23 patients with intractable respiratory failure
were given ECMO support and placed on the lung transplantrdiovascular Surgery c Volume 140, Number 2 429
TABLE 3. Comparison of patients who needed extracorporeal
membrane oxygenation after lung transplant with those who did not
Posttransplant ECMO
Yes No
No. of transplants 22 322
Age (y, median and range) 8.2 (1–21) 12.1 (0.1–18)
Sex (female/male) 13:9 177:145
Diagnoses (no.)
Cystic fibrosis 6 (27%) 161 (50%)
Pulmonary hypertension 5 (23%) 53 (17%)
Bronchiolitis obliterans 4 (18%) 40 (12%)
Pulmonary fibrosis 2 (9%) 32 (10%)
Adult respiratory distress syndrome 2 (9%) 0
Other 3 (13%) 36 (11%)
Single/double transplant ratio 2:20 7:315
ICU stay (d, median and range) 14 (3–88) 7 (0–164)
Hospital stay (d, median and range) 17 (3–145) 19 (1–261)
Ischemic time (min, median and range)
Left 271 254
Right 281 385
Major complications* (no.) 18 (82%) 83 (26%)
Survival to discharge (no.) 5 (23%) 296 (92%)
Survival at 1 y (no.) 4 (18.2%) 265 (82.3%)
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit. *Major
complications were bleeding, stroke, reexploration, and infection.
TABLE 4. Comparison of survivors and nonsurvivors among patients
who required extracorporeal membrane oxygenation after lung
transplant
Survivors Nonsurvivors
No. of patients 5 17
No. of ECMO runs 6 18
Age (y, median and range) 9.2 (1.8–17) 3.9 (0.2–21)
Sex (female/male) 3:2 10:7
Diagnoses (no.)
Cystic fibrosis (n ¼ 6) 1 (20%) 5 (29%)
Pulmonary hypertension (n ¼ 5) 2 (40%) 3 (18%)
Bronchiolitis obliterans (n ¼ 4) 1 (20%) 3 (18%)
Pulmonary fibrosis (n ¼ 2) 0 2 (12%)
Adult respiratory distress
syndrome (n ¼ 2)
0 2 (12%)
Other (n ¼ 3) 1 (20%) 2 (12%)
Pretransplant ECMO (no.) 0 4
Postoperative ECMO duration
(h, median and range)
91 (48–408) 152 (25–505)
ICU stay (d, median and range) 40 (3–41) 14 (8–74)
Hospital stay (d, median and range) 40 (10–96) 14 (3–110)
Ischemic time (min, median and range)
Left 330 281
Right 314 303
Indication for ECMO runs (no.)
Primary graft dysfunction (n ¼ 18) 4 14
Pneumonia (n ¼ 4) 2 2
Other (n ¼ 2) 0 2
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit.
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Xlist. Eventually, 15 of these patients underwent lung trans-
plant, whereas the remaining 8 patients died before lung
transplant. In a report from Kirshbom and colleagues,10 8
children were given ECMO support in an attempt to bridge
to lung transplant. None of these patients survived to lung
transplant or discharge after a mean ECMO run of 588
hours. This highlights the problem of demand–supply mis-
match in pediatric lung transplantation and emphasizes the
importance of patient selection when considering the use
of ECMO in the pretransplant setting. Children younger
than 12 years are not prioritized by the Lung Allocation
Score system used for older children and adults. A child
older than 12 years would predictably have a higher Lung
Allocation Score and thus get offers in a more timely fashion
than an infant.
An interesting recent development has been the use of
newer lung replacement technologies. The interventional
lung assist NovaLung (iLA; NovaLung GmbH, Hechingen,
Germany) is a low-resistance lung assist device designed for
pulsatile blood flow with tight diffusion membranes and
a protein matrix coating.16 It is driven by the cardiac output
and therefore does not require extracorporeal pump assis-
tance. The Hannover group17 described 12 patients with iso-
lated hypercapnic respiratory failure who were supported
with this device; of these, 10 were successfully bridged to
lung transplant. At 1 year, 8 patients were alive.17 Since
then, Fischer and associates18 from Hannover have com-
bined this device with a pump and used it for both hypercap-
nic and hypoxic respiratory failure in the pretransplant430 The Journal of Thoracic and Cardiovascular Surgsetting. The use of the NovaLung device has not been de-
scribed in the pediatric population.
ECMO support has been used more commonly after lung
transplant. Several series describe 1-year survivals ranging
from 26% to 47% when ECMO support is used (predomi-
nantly for PGD) in the adult population.3-5,7,8,19 Kirshbom
and colleagues10 reported a cohort of 8 children requiring
ECMO support after lung or heart–lung transplants with
an encouraging hospital discharge rate of 63%. Our own
hospital discharge rate for posttransplant ECMO support
was 5 of 18 (28%) after exclusion of patients already sup-
ported by ECMO before lung transplant. Mason and co-
workers5 from the Cleveland Clinic reported 1-year
survivals of 41% with ECMO for PGD but only 3% with
ECMO support for posttransplant pneumonia or sepsis. In
our series, of the 6 ECMO runs in patients who survived
to hospital discharge, 4 were for PGD and 2 for pneumonia.
This may have been due to chance, because the numbers in-
volved were small, or it may represent a difference between
the adult and pediatric populations.
Hartwig and associates6 reported superior outcomes after
venovenous ECMO versus venoarterial ECMO for post-
transplant PGD. In their experience comparing venoarterial
with venovenous cannulation, they reported a 30-day sur-
vival of 88% in the venovenous group (n ¼ 8), as opposedery c August 2010
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also noted that the venoarterial group had 30 severe compli-
cations, compared with 9 complications in the venovenous
group. For children who require ECMO support for respira-
tory reasons, the venoarterial mode is often used with con-
cerns about hemodynamic instability developing from
respiratory failure. We used venovenous ECMO on 1 occa-
sion recently for posttransplant pneumonia, and the patient is
alive at 10 months. We are now more likely to use the veno-
venous configuration in the appropriate clinical setting.
Interestingly, we noted that the mean time for institution
of ECMO for PGD after lung transplant was shorter for
the 4 survivors than for the 14 nonsurvivors (8.5 hours vs
75 hours). Although the number of patients was small, this
may indicate that patients who are supported with ECMO
earlier may do better than patients who are treated with lon-
ger periods of more aggressive ventilatory strategies before
resorting to ECMO. We are now more likely to consider ear-
lier institution of ECMO rather than persisting with aggres-
sive ventilatory strategies in managing severe PGD.
CONCLUSIONS
The need for perioperative ECMO support is associated
with significant morbidity and mortality in the pediatric
lung transplant population. A subset of patients who can
be weaned from ECMO in the preoperative setting have
greater likelihood of survival. Extracorporeal support should
be cautiously offered to children with intractable respiratory
failure who are awaiting a primary (not reoperative) lung
transplant and to children with severe PGD or pneumonia af-
ter lung transplant for whom more conservative therapy does
not work. Earlier institution of ECMO for severe PGD may
possibly be protective.
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Dr Victor Morell (Pittsburgh, Pa). Dr Puri and associates pre-
sented their extensive experience with preoperative and postopera-
tive ECMO support in their pediatric lung transplant population. I
would have to admit that at Children’s Hospital of Pittsburgh, we
consider preoperative ECMO a contraindication for lung trans-
plant; however, there is certainly adult literature that would support
transplants for patients with ECMO support, and the results have
been reasonable.
I have 3 questions, Dr Puri. With the limited availability of or-
gans, what is the current management at your institution for patients
with ECMO support? Are they still listed?
Dr Puri. The short answer is no, and our results reflect that. We
had lower than 15% survival for patients supported by ECMO go-
ing into lung transplantation, and organs, as you say, are scarce.
Therefore we delist the patients when they are supported by
ECMO.
DrMorell. The second question is, I was a little surprised at the
poor outcome of postoperative ECMO, the patients who required
ECMO after transplant. Do you have some insight into why such
poor results with postoperative ECMO?
Dr Puri. Dr Morell, I take it that you are referring to a compar-
ison between pediatric and adult literature?
Dr Morell. I mean, we don’t have an extensive experience with
postoperative ECMO either, but I would expect a higher survival
among patients who only require postoperative ECMO if they
were reasonable candidates before operation and received reason-
able lungs. I just wonder, why do you think the survival was so
poor for patients who required postoperative ECMO?rdiovascular Surgery c Volume 140, Number 2 431
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XDr Puri. Just to put things into perspective, when the adult pop-
ulation requires postoperative ECMO, survivals range between
40% and 65%, depending on the study. For our patients, the general
perception was that if they required posttransplant ECMO, they
were sicker patients going into the procedure. I believe that we
have erroneously had a strategy of performing aggressive ventila-
tory strategies on freshly implanted lungs for longer periods, which
is something that we have reversed recently. Finally, in this partic-
ular patient population, there are somewhat higher incidences of
pulmonary hypertension and bronchiolitis obliterans than in the
general transplant population, either pediatric or adult.
DrMorell. I guess my final question is somewhat similar to that.
About 6% of your patients required postoperative ECMO, and I’m
just wondering whether you had a chance to look at any preopera-
tive variables that might help to identify patients who might be at
risk for postoperative ECMO.
Dr Puri. The combined incidence of bronchiolitis obliterans and
pulmonary hypertension was somewhat higher in the ECMO
group. It was 28% or so for the general population and 41% for
this particular group.
Dr Morell. Thank you.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Puri, am I
to understand that you had 3 patients in the preoperative ECMO
group with an indication of primary graft failure?
Dr Puri.One patient had primary graft failure and 2 patients had
bronchiolitis obliterans. I grouped them together as having PGD.
Dr Keshavjee. So the patient with the primary graft failure
would have been counted twice?
Dr Puri. Counted both in the preoperative and postoperative
ECMO groups.
Dr Keshavjee. But in the postoperative ECMO group the first
time around, and then the preoperative ECMO group, and then
again in the postoperative ECMO group?
Dr Puri. Correct.432 The Journal of Thoracic and Cardiovascular SurgDr Waleed Saleh (Riyadh, Saudi Arabia). You mentioned that
if you started the ECMO early, the outcome was better than with
a late start, and this is well documented in adult transplantation.
Do you have criteria to start the ECMO?
Dr Puri. A number of parameters are looked at by the team
taking care of patients: oxygenation, our ability to ventilate these
lungs without excessive airway pressures, systemic hemody-
namic compromise, and the trajectory of the clinical course in
the few hours after transplantation. In our earlier experience,
we did not have this insight, so we had long periods of using ag-
gressive ventilatory strategies on these freshly implanted lungs. I
think that was a bad idea, and we have recognized this lately and
are moving further and further toward earlier institution of
ECMO if we think the clinical trajectory is headed in the wrong
direction.
Dr Saleh. Thank you. Nice article.
Dr Puri. Dr Keshavjee, may I solicit a comment from you?
Dr Keshavjee. Sure.
Dr Puri. I believe that you have the most extensive North Amer-
ican NovaLung program. Are there any pediatric NovaLung appli-
cations that you’ve had, Dr Keshavjee?
Dr Keshavjee. Yes. Well, the NovaLung can run from 0.5 L to
4.5 L/min, so it’s capable of bridging kids to transplant. We have
only used the NovaLung as opposed to the standard ECMO setup
once, and we did it with the PA-to-LA setting. But I do think the
technology is getting better. The one thing that has come up, we
have all learned that in the posttransplant phase, if you’re going
to do it, just do it sooner. Every time we have regretted waiting lon-
ger, and we have had much smoother and shorter runs when we
have put it on early, almost to the point where you wonder whether
you could have gotten by without it. I think the most important
take-home message is that in the posttransplant period, you should
resort to it sooner than later, before you’ve got a very bad problem
on your hands.ery c August 2010
